Predilife S.A. (EPA:ALPRE)

Market Cap	9.82M -29.0%
Revenue (ttm)	728.08K +142.0%
Net Income	-3.80M
EPS	-1.00
Shares Out	3.78M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	301
Open	2.620
Previous Close	2.640
Day's Range	2.600 - 2.620
52-Week Range	2.300 - 4.000
Beta	0.27
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 15, 2026

About Predilife

Predilife S.A. designs and markets predictive tests for the occurrence of serious illnesses. The company provides breast cancer predictive assessment; multi-pathology predictive assessment; and the Care4Eat solution, a nutrition assessment that allows employees to take stock of their eating habits and benefit from rebalancing and personalized advice. It also offers MammoRisk, a breast cancer prediction test based on the patient’s individual risk; and DenSeeMammo, a breast density measurement software. Predilife S.A. was incorporated in 2004 and...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2004
• Employees: 27
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALPRE

Financial Performance

In 2024, Predilife's revenue was 493,202, an increase of 55.20% compared to the previous year's 317,794. Losses were -4.26 million, 0.96% more than in 2023.